Novartis Launching Hypertension Awareness Campaign With $25 Mil. Ad Spend
This article was originally published in The Pink Sheet Daily
Executive Summary
Disease awareness campaign encourages earlier and more aggressive treatment of high blood pressure, Novartis says. Diovan, Lotrel prescriptions already responding to two-week-old program.
You may also be interested in...
Novartis' Unbranded Diovan Ads Draw FDA Scrutiny
FDA has concerns that the unbranded ad, which is connected to a disease awareness program, too heavily references Novartis. The company has its own concerns that unbranded ads may not be effective in the anti-hypertensive market.
Novartis' Unbranded Diovan Ads Draw FDA Scrutiny
FDA has concerns that the unbranded ad, which is connected to a disease awareness program, too heavily references Novartis. The company has its own concerns that unbranded ads may not be effective in the anti-hypertensive market.
Novartis Diovan Promotions Draw FDA Warning Letter For Diabetes Claims
The MARVAL study cited in the sales materials does not demonstrate that the antihypertensive is effective in preserving renal function, FDA's ad division says. The letter preceded Novartis' unveiling of a hypertension disease awareness campaign.